This is NOT cancer—you have an inflammatory myopathy, most likely mixed connective tissue disease (MCTD) or overlap syndrome.
Your anti-U1-RNP antibodies at 86 U (reference <20) with proximal muscle weakness and elevated CK strongly suggest an autoimmune inflammatory myopathy, not malignancy. While certain myositis subtypes carry cancer risk, anti-U1-RNP positivity is actually associated with MCTD/overlap syndromes that have low cancer risk 1.
Understanding Your Diagnosis
Your clinical picture points to an inflammatory myopathy with these key features:
- Proximal muscle weakness (arms, legs, hips, thighs) = hallmark of myositis
- Elevated CK at 527 U/L (upper limit 439) = muscle inflammation
- Anti-U1-RNP antibodies = specific for MCTD/overlap syndrome
- ANA 1:160 speckled pattern = consistent with connective tissue disease
- Normal kidney/liver function = good prognostic sign
The EMG and potential muscle biopsy will confirm myopathy and guide treatment 2.
Cancer Risk Assessment
You are at LOW risk for myositis-associated cancer based on:
- Anti-U1-RNP antibodies are NOT high-risk autoantibodies for cancer. High-risk antibodies include anti-TIF1γ, anti-NXP2, and anti-SAE1—none of which you have 1
- You're 30 years old (cancer-associated myositis typically occurs >40 years)
- No "red flag" symptoms mentioned (unintentional weight loss, unexplained fever, night sweats, family history of cancer) 1
According to 2023 international guidelines, you would be classified as "standard risk of IIM-related cancer" and require only age-appropriate cancer screening for the general population—not enhanced surveillance 1.
Your Specific Concerns
"How fucked am I?"
You're not fucked—this is treatable. At 30 years old with:
- ✓ Normal organ function
- ✓ Low cancer-risk antibody profile
- ✓ Early diagnosis (getting EMG/biopsy promptly)
- ✓ Treatable condition with immunosuppression
Expected treatment approach 2:
- Corticosteroids (prednisone 0.5-1 mg/kg) as first-line therapy
- Steroid-sparing agents (methotrexate, azathioprine, or mycophenolate) added early
- Physical therapy once inflammation controlled
- Most patients achieve good functional recovery with treatment
GLP-1 Receptor Agonist Use
Continue your GLP-1 therapy for weight loss—there is no contraindication with inflammatory myopathy 3, 4. Weight loss will actually help reduce:
- Mechanical stress on inflamed muscles
- Cardiovascular risk factors
- Overall inflammatory burden
G6PD Deficiency at 41 U/L
This matters for medication safety but doesn't affect your myositis prognosis 5, 6, 7.
Critical medications to AVOID with G6PD deficiency:
- Rasburicase (high risk)
- Primaquine (high risk)
- Dapsone (high risk)
- Methylene blue (high risk)
Medications you CAN use safely:
- Corticosteroids (prednisone, methylprednisolone)
- Methotrexate
- Azathioprine
- Mycophenolate
- NSAIDs (with standard precautions)
- GLP-1 receptor agonists
Inform all prescribers of your G6PD deficiency to avoid oxidative stress triggers 5, 6.
Next Steps Algorithm
Immediate (this week):
- Complete EMG (Thursday)—will show myopathic changes (short-duration, low-amplitude polyphasic potentials with fibrillations) 2
- If EMG confirms myopathy → muscle biopsy from weak muscle on opposite side
- Check troponin and ECG to rule out cardiac involvement (critical—myocarditis is life-threatening) 8
- Baseline chest imaging to assess for interstitial lung disease (can occur with MCTD)
Within 2 weeks:
- Rheumatology referral (urgent—don't wait) 8
- Start prednisone 0.5-1 mg/kg if biopsy confirms inflammatory myopathy 2
- Monitor CK, ESR, CRP weekly initially 8
Within 1 month:
- Add steroid-sparing agent (methotrexate or azathioprine) to minimize long-term steroid exposure 2
- Physical therapy once inflammation controlled
- PCP prophylaxis if on high-dose steroids >12 weeks 8
Common Pitfalls to Avoid
Do NOT:
- Delay treatment waiting for "perfect" diagnosis—early treatment prevents irreversible muscle damage
- Use NSAIDs alone—insufficient for inflammatory myositis 9
- Assume this is just "weakness from obesity"—the elevated CK and autoantibodies prove otherwise
- Take oxidative medications without checking G6PD safety first
Do:
- Get cardiac evaluation (troponin, ECG, consider echo)—myocarditis is the most dangerous complication 8
- Report any dysphagia, dyspnea, or chest pain immediately
- Continue weight loss efforts—obesity worsens outcomes
Bottom Line
You have an autoimmune inflammatory myopathy (likely MCTD/overlap syndrome), NOT cancer. Your prognosis is good with appropriate immunosuppressive treatment. The anti-U1-RNP antibody profile actually indicates lower cancer risk compared to other myositis subtypes. Your G6PD deficiency requires medication awareness but doesn't limit standard myositis treatment. Get the EMG, see rheumatology urgently, and start treatment—most patients achieve significant improvement within 3-6 months.